239 related articles for article (PubMed ID: 24613115)
21. [Evaluation of immunohistochemical markers for differential diagnosis of hepatocellular carcinoma from intrahepatic cholangiocarcinoma].
Dong H; Cong WL; Zhu ZZ; Wang B; Xian ZH; Yu H
Zhonghua Zhong Liu Za Zhi; 2008 Sep; 30(9):702-5. PubMed ID: 19173916
[TBL] [Abstract][Full Text] [Related]
22. Hepatocyte paraffin 1 antibody does not distinguish primary ovarian tumors with hepatoid differentiation from metastatic hepatocellular carcinoma.
Pitman MB; Triratanachat S; Young RH; Oliva E
Int J Gynecol Pathol; 2004 Jan; 23(1):58-64. PubMed ID: 14668552
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic utility of CD10 in differentiating hepatocellular carcinoma from metastatic carcinoma in fine-needle aspiration biopsy (FNAB) of the liver.
Lin F; Abdallah H; Meschter S
Diagn Cytopathol; 2004 Feb; 30(2):92-7. PubMed ID: 14755758
[TBL] [Abstract][Full Text] [Related]
24. The alphavbeta6 integrin is a highly specific immunohistochemical marker for cholangiocarcinoma.
Patsenker E; Wilkens L; Banz V; Osterreicher CH; Weimann R; Eisele S; Keogh A; Stroka D; Zimmermann A; Stickel F
J Hepatol; 2010 Mar; 52(3):362-9. PubMed ID: 20137822
[TBL] [Abstract][Full Text] [Related]
25. KL-6 mucin is a useful immunohistochemical marker for cholangiocarcinoma.
Tang W; Guo Q; Qu X; Inagaki Y; Seyama Y; Midorikawa Y; Gai R; Kokudo N; Sugawara Y; Nakata M; Makuuchi M
Oncol Rep; 2007 Apr; 17(4):737-41. PubMed ID: 17342308
[TBL] [Abstract][Full Text] [Related]
26. Diagnostic utility of the HepPar1 antibody to differentiate hepatocellular carcinoma from metastatic carcinoma in fine-needle aspiration samples.
Siddiqui MT; Saboorian MH; Gokaslan ST; Ashfaq R
Cancer; 2002 Feb; 96(1):49-52. PubMed ID: 11836703
[TBL] [Abstract][Full Text] [Related]
27. [Immunohistochemical spectrum in the detection and differentiation of intrahepatic neoplasms].
Cong W; Tan L; Zhang S; Xian Z; Wu W; Pan J; Zhang X
Zhonghua Zhong Liu Za Zhi; 2002 Nov; 24(6):553-6. PubMed ID: 12667323
[TBL] [Abstract][Full Text] [Related]
28. Best practices in diagnostic immunohistochemistry: hepatocellular carcinoma versus metastatic neoplasms.
Kakar S; Gown AM; Goodman ZD; Ferrell LD
Arch Pathol Lab Med; 2007 Nov; 131(11):1648-54. PubMed ID: 17979482
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic value of HepPar1, pCEA, CD10, and CD34 expression in separating hepatocellular carcinoma from metastatic carcinoma in fine-needle aspiration cytology.
Saad RS; Luckasevic TM; Noga CM; Johnson DR; Silverman JF; Liu YL
Diagn Cytopathol; 2004 Jan; 30(1):1-6. PubMed ID: 14696137
[TBL] [Abstract][Full Text] [Related]
30. Hep Par 1 in gastric and bowel carcinomas: an immunohistochemical study.
Villari D; Caruso R; Grosso M; Vitarelli E; Righi M; Barresi G
Pathology; 2002 Oct; 34(5):423-6. PubMed ID: 12408340
[TBL] [Abstract][Full Text] [Related]
31. Immunohistochemical characterization of canine hyperplastic hepatic lesions and hepatocellular and biliary neoplasms with monoclonal antibody hepatocyte paraffin 1 and a monoclonal antibody to cytokeratin 7.
Ramos-Vara JA; Miller MA; Johnson GC
Vet Pathol; 2001 Nov; 38(6):636-43. PubMed ID: 11732796
[TBL] [Abstract][Full Text] [Related]
32. Hepatocellular carcinoma metastatic to skin: diagnostic utility of antihuman hepatocyte antibody in combination with albumin in situ hybridization.
Wood AJ; Lappinga PJ; Ahmed I
J Cutan Pathol; 2009 Feb; 36(2):262-6. PubMed ID: 18727662
[TBL] [Abstract][Full Text] [Related]
33. Agrin immunohistochemistry facilitates the determination of primary versus metastatic origin of liver carcinomas.
Somorácz A; Tátrai P; Horváth G; Kiss A; Kupcsulik P; Kovalszky I; Schaff Z
Hum Pathol; 2010 Sep; 41(9):1310-9. PubMed ID: 20471664
[TBL] [Abstract][Full Text] [Related]
34. The diagnostic value of cytokeratins and carcinoembryonic antigen immunostaining in differentiating hepatocellular carcinomas from intrahepatic cholangiocarcinomas.
Stroescu C; Herlea V; Dragnea A; Popescu I
J Gastrointestin Liver Dis; 2006 Mar; 15(1):9-14. PubMed ID: 16680226
[TBL] [Abstract][Full Text] [Related]
35. Immunohistochemical evaluation of hepatoblastomas with use of the hepatocyte-specific marker, hepatocyte paraffin 1, and the polyclonal anti-carcinoembryonic antigen.
Fasano M; Theise ND; Nalesnik M; Goswami S; Garcia de Davila MT; Finegold MJ; Greco MA
Mod Pathol; 1998 Oct; 11(10):934-8. PubMed ID: 9796718
[TBL] [Abstract][Full Text] [Related]
36. Comparative immunohistochemical expression of p63 in human cholangiocarcinoma and hepatocellular carcinoma.
Ramalho FS; Ramalho LN; Della Porta L; Zucoloto S
J Gastroenterol Hepatol; 2006 Aug; 21(8):1276-80. PubMed ID: 16872309
[TBL] [Abstract][Full Text] [Related]
37. Diagnostic role of glypican 3 and CD34 for differentiating hepatocellular carcinoma from nonmalignant hepatocellular lesions.
Enan ET; El-Hawary AK; El-Tantawy DA; Abu-Hashim MM; Helal NM
Ann Diagn Pathol; 2013 Dec; 17(6):490-3. PubMed ID: 24012547
[TBL] [Abstract][Full Text] [Related]
38. Branched chain in situ hybridization for albumin as a marker of hepatocellular differentiation: evaluation of manual and automated in situ hybridization platforms.
Shahid M; Mubeen A; Tse J; Kakar S; Bateman AC; Borger D; Rivera MN; Ting DT; Deshpande V
Am J Surg Pathol; 2015 Jan; 39(1):25-34. PubMed ID: 25353287
[TBL] [Abstract][Full Text] [Related]
39. A comparison of CD10 to pCEA, MOC-31, and hepatocyte for the distinction of malignant tumors in the liver.
Morrison C; Marsh W; Frankel WL
Mod Pathol; 2002 Dec; 15(12):1279-87. PubMed ID: 12481008
[TBL] [Abstract][Full Text] [Related]
40. Combined fibrolamellar carcinoma and cholangiocarcinoma exhibiting biphenotypic antigen expression: a case report.
Tanaka K; Honna T; Kitano Y; Kuroda T; Tanaka K; Morikawa N; Matsuda H; Kawashima N; Matsuoka K; Miyauchi J
J Clin Pathol; 2005 Aug; 58(8):884-7. PubMed ID: 16049296
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
